Keros Therapeutics, Inc.KROSNASDAQ

Revenue (LTM)

$244M

+6775.0% YoY

Net Income (LTM)

$87M

+146.4% YoY

Free Cash Flow

$106M

Revenue CAGR (5Y)

—

—Marginsstable

FCFTurned positive

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	20	0	0	4↑2251.0%	244↑6775.0%
Gross Profit	20	0	0	4↑2251.0%	243↑6732.5%
Operating Income	-56	-115↓103.6%	-170↓48.0%	-211↓24.1%	71↑133.5%
Net Income	-59	-105↓78.2%	-153↓46.2%	-187↓22.5%	87↑146.4%
EBITDA	-56	-104↓84.6%	-152↓46.3%	-186↓22.1%	72↑138.8%
EPS Diluted	-2.52	-4.15↓64.7%	-5.20↓25.3%	-5.00↑3.8%	2.30↑146.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	230	279↑21.3%	331↑18.7%	560↑69.1%	287↓48.7%
Total Current Assets	251	286↑13.7%	347↑21.5%	589↑69.6%	315↓46.4%
Total Assets	255	307↑20.2%	370↑20.6%	616↑66.4%	338↓45.1%
Total Current Liabilities	12	17↑39.7%	24↑47.3%	27↑12.6%	20↓25.6%
Total Liabilities	12	29↑143.1%	38↑28.8%	44↑17.2%	35↓21.3%
Total Equity	243	277↑14.1%	332↑19.7%	572↑72.0%	303↓47.0%
Total Debt	1	13↑1113.7%	14↑8.9%	19↑30.6%	17↓10.5%
Net Debt	-229	-266↓16.1%	-317↓19.2%	-541↓70.8%	-271↑50.0%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-62	-70↓12.7%	-125↓77.7%	-161↓29.2%	108↑166.8%
Capital Expenditure	-1	-1↓21.2%	-2↓98.5%	-2↑21.6%	-2↑19.7%
Free Cash Flow	-63	-71↓12.9%	-127↓78.1%	-163↓28.2%	106↑165.1%
Stock-Based Comp	12	19↑59.4%	29↑54.0%	35↑21.2%	29↓17.7%
Net Change in Cash	-35	49↑241.5%	52↑6.1%	229↑340.6%	-273↓219.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance